Celon Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Celon Pharma wird ein jährliches Gewinn- und Umsatzwachstum von 14.4% bzw. 3.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich sinken um 17.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -0.4% betragen.

Wichtige Informationen

14.4%

Wachstumsrate der Gewinne

-17.8%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	15.8%
Wachstumsrate der Einnahmen	3.2%
Zukünftige Eigenkapitalrendite	-0.4%
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Sep 24

Recent updates

A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price

Aug 21

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Sep 24

Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Feb 09

Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Jan 20

Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Dec 24

Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Dec 03

Gewinn- und Umsatzwachstumsprognosen

WSE:CLN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (PLN Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	273	5	28	57	4
12/31/2025	328	51	16	90	4
12/31/2024	232	-20	29	23	4
9/30/2024	280	19	-33	-17	N/A
6/30/2024	207	-45	-12	6	N/A
3/31/2024	209	-34	-23	2	N/A
12/31/2023	214	-28	-41	-8	N/A
9/30/2023	214	-25	-31	7	N/A
6/30/2023	211	-30	-53	-16	N/A
3/31/2023	196	-47	-42	-8	N/A
12/31/2022	194	-39	-39	-5	N/A
9/30/2022	191	-31	-39	-10	N/A
6/30/2022	186	-28	-11	32	N/A
3/31/2022	191	-17	-17	25	N/A
12/31/2021	196	-12	3	44	N/A
9/30/2021	186	-11	7	60	N/A
6/30/2021	185	-2	3	57	N/A
3/31/2021	170	0	-18	71	N/A
12/31/2020	157	-1	-28	72	N/A
9/30/2020	142	4	-58	37	N/A
6/30/2020	128	5	-88	6	N/A
3/31/2020	109	3	-85	-19	N/A
12/31/2019	102	12	-70	-5	N/A
9/30/2019	110	17	-69	6	N/A
6/30/2019	118	23	-61	15	N/A
3/31/2019	124	29	-31	37	N/A
12/31/2018	125	30	-39	28	N/A
9/30/2018	116	30	-30	27	N/A
6/30/2018	109	26	N/A	34	N/A
3/31/2018	107	28	N/A	26	N/A
12/31/2017	107	26	N/A	25	N/A
9/30/2017	129	22	N/A	18	N/A
6/30/2017	127	24	N/A	23	N/A
3/31/2017	115	27	N/A	28	N/A
12/31/2016	129	38	N/A	21	N/A
9/30/2016	111	42	N/A	34	N/A
12/31/2015	108	37	N/A	52	N/A
12/31/2014	98	52	N/A	24	N/A
12/31/2013	72	18	N/A	8	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CLNDas prognostizierte Gewinnwachstum (14.4% pro Jahr) liegt über der Sparquote (4.1%).

Ertrag vs. Markt: CLNDie Erträge des Unternehmens (14.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Polish (15.3% pro Jahr).

Hohe Wachstumserträge: CLNDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: CLNDie Einnahmen des Unternehmens (3.2% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Polish (4% pro Jahr).

Hohe Wachstumseinnahmen: CLNDie Einnahmen des Unternehmens (3.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CLN wird voraussichtlich in 3 Jahren unrentabel sein.

Celon Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 26% to zł21.10

Consensus estimates of losses per share improve by 50%

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

Price target decreased to zł27.55

Price target decreased to zł27.55

Price target decreased to zł29.32

Recent updates

Third quarter 2024 earnings released: EPS: zł1.06 (vs zł0.13 loss in 3Q 2023)

Second quarter 2024 earnings released: zł0.15 loss per share (vs zł0.18 profit in 2Q 2023)

A Piece Of The Puzzle Missing From Celon Pharma S.A.'s (WSE:CLN) Share Price

New minor risk - Shareholder dilution

Price target increased by 26% to zł21.10

Celon Pharma S.A. Announces Strong Proof-Of-Concept Data from Phase 2 Trial of PDE10A Inhibitor (CPL'36), a Novel Oral Antipsychotic

Now 67% overvalued after recent price rise

Upcoming dividend of zł0.08 per share

Celon Pharma Announces Results of Phase Ii Clinical Trial for Cpl’ 116, A Jak/Rock Dual Inhibitor in the Treatment of Rheumatoid Arthritis (Ra)

Now 21% overvalued

Full year 2023 earnings released: zł0.55 loss per share (vs zł0.77 loss in FY 2022)

Consensus estimates of losses per share improve by 50%

Celon Pharma S.A. to Report Fiscal Year 2023 Results on Apr 24, 2024

Third quarter 2023 earnings released

Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released

Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans

Upcoming dividend of zł0.09 per share at 0.6% yield

Full year 2022 earnings released

Celon Pharma S.A. to Report Q3, 2023 Results on Nov 22, 2023

Third quarter 2022 earnings released

Price target decreased to zł27.55

We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow

Price target decreased to zł27.55

Price target decreased to zł29.32

Second quarter 2022 earnings released

We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth

Consensus EPS estimates fall by 27%

Upcoming dividend of zł0.29 per share

Price target decreased to zł32.32

Consensus forecasts updated

Celon Pharma S.A., Annual General Meeting, Jun 22, 2022

Price target decreased to zł36.12

Consensus EPS estimates fall by 36%

Price target decreased to zł40.72

Price target decreased to zł43.23

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to zł45.23

Price target decreased to zł48.23

Second quarter 2021 earnings released: EPS zł0.01 (vs zł0.25 in 2Q 2020)

Upcoming dividend of zł0.07 per share

Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes

Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly

Price target increased to zł54.07

Celon Pharma Terminates Cooperation with Lupin Atlantis Holdings

Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)

Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor

Price target raised to zł50.30

Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Celon Pharma S.A. to Report Fiscal Year 2020 Results on Mar 31, 2021

Celon Pharma S.A. to Report Q1, 2021 Results on May 31, 2021

Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?

Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression

Investor sentiment improved over the past week

New 90-day high: zł43.45

Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain

Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet

Third quarter 2020 earnings released: EPS zł0.088

Market bids up stock over the past week

New 90-day low: zł38.25

First half earnings released

New 90-day high - zł44.25

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken